[1]孙斌,刘举珍,张飞飞.SPECT/CT断层融合显像联合血清CEA、CYFRA21-1在诊断非小细胞肺癌骨转移中的应用[J].国际放射医学核医学杂志,2018,(3):212-217.[doi:10.3760/cma.j.issn.1673-4114.2018.03.004]
　Sun Bin,Liu Juzhen,Zhang Feifei.Application of SPECT/CT tomographic fusion imaging combined with serum CEA and CYFRA21-1 in the diagnosis of bone metastasis of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):212-217.[doi:10.3760/cma.j.issn.1673-4114.2018.03.004]
点击复制

SPECT/CT断层融合显像联合血清CEA、CYFRA21-1在诊断非小细胞肺癌骨转移中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第3期
页码:
212-217
栏目:
单光子显像在临床中的应用
出版日期:
2018-05-25

文章信息/Info

Title:
Application of SPECT/CT tomographic fusion imaging combined with serum CEA and CYFRA21-1 in the diagnosis of bone metastasis of non-small cell lung cancer
作者:
孙斌;  刘举珍;  张飞飞
010017 呼和浩特, 内蒙古自治区人民医院核医学科
Author(s):
Sun Bin;  Liu Juzhen;  Zhang Feifei
Department of Nuclear Medicine, Inner Mongolia People’s Hospital, Hohhot 010017, China
关键词:
癌; 非小细胞肺; 肿瘤转移; 单光子发射计算机体层摄影术; 癌胚抗原; 可溶性细胞角蛋白19片段
Keywords:
Carcinoma; non-small-cell lung; Neoplasm metastasis; Single photon emission computed tomography computed tomography; Carcinoembryonic antigen; Cytokeratin-19-fragment
DOI:
10.3760/cma.j.issn.1673-4114.2018.03.004
摘要:
目的 研究SPECT/CT断层融合显像联合血清肿瘤标志物癌胚抗原（CEA）、可溶性细胞角蛋白19片段（CYFRA21-1）在诊断非小细胞肺癌（NSCLC）骨转移中的应用。方法 选取143例经病理确诊为NSCLC的患者（腺癌88例，鳞癌55例），抽取其静脉血测定血清CEA、CYFRA21-1的水平，并行全身骨显像和SPECT/CT融合显像。血清CEA、CYFRA21-1之间的比较采用Mann-Whitney U秩和检验。血清CEA、CYFRA21-1水平与骨转移数目的相关性采用Spearman相关性分析；肺腺癌和肺鳞癌骨转移的发生率、骨转移灶数目、全身骨显像、SPECT/CT同机断层融合显像与血清CEA、CYFRA21-1单用或联合应用诊断骨转移的灵敏度、特异度和准确率的比较采用χ2检验。结果 68例患者证实发生骨转移，病灶共有586个。腺癌骨转移发生率（50/88）高于鳞癌（18/55）（χ2=10.56，P<0.05）；腺癌骨转移病灶数比例（526/586）大于鳞癌（χ2=19.23，P<0.05）；骨转移患者的血清CEA（Z=4.98，P<0.05）、CYFRA21-1（Z=2.55，P<0.05）水平高于未发生骨转移患者；NSCLC骨转移患者血清CEA与骨转移灶的数目无显著相关性（r=0.141， P>0.05），而CYFRA21-1与骨转移灶的数目具有一定相关性（r=0.502，P<0.01）。血清CEA、CYFRA21-1水平诊断NSCLC骨转移具有一定的灵敏度（69.1%、83.8%），但特异度（47.6%、49.3%）、准确率（57.3%、65.7%）较低，而SPECT/CT同机断层融合显像在诊断NSCLC骨转移时具有较高的灵敏度（83.8%）、特异度（84.0%）、准确率（83.9%），高于血清CEA（χ2=4.09、23.08、24.33，均P<0.05），特异度和准确率高于CYFRA21-1（χ2=20.28、12.55，均P<0.05）及全身骨显像（χ2=21.66、16.05，均P<0.05）。而SPECT/CT同机断层融合显像联合血清CEA及CYFRA21-1诊断NSCLC骨转移的灵敏度（97.0%）、特异度（93.3%）、准确率（95.1%）分别高于血清CEA（χ2=18.89、38.89、24.33，均P<0.05）、CYFRA21-1（χ2=6.89、35.50、39.17，均P<0.05）、单独应用全身骨显像（χ2=12.55、37.17、47.45，均P<0.05），灵敏度、准确率高于单独应用SPECT/CT同机断层融合显像（χ2=6.89、9.53，均P<0.05）。结论 SPECT/CT断层融合显像联合血清CEA、CYFRA21-1诊断NSCLC骨转移的发生具有较高的灵敏度、特异度、准确率，在临床工作中具有一定的应用价值。
Abstract:
Objective This study aims to study the role of SPECT/CT tomographic fusion imaging in combination with serum tumor markers such as CEA and CYFRA21-1 to diagnose bone metastasis of NSCLC. Methods A total of 143 patients with pathologically confirmed NSCLC were selected as study subjects(adenocarcinoma 88 cases, squamous cell 55 cases). Venous blood samples were collected to determine the serum levels of CEA and CYFRA21-1, and a whole body bone scan and SPECT/CT tomographic fusion imaging was performed. SPSS 22.0 software was used to compare serum CEA with CYFRA21-1 with the Mann-Whitney U rank sum test. Spearman correlation analysis was used to correlate serum CEA and CYFRA21-1 levels with the number of bone metastases. Sensitivity, specificity, and accuracy in the diagnosis of bone metastases were needed to detect the incidence of bone metastases in lung adenocarcinoma and squamous cell carcinoma of the lung via whole-body bone imaging and SPECT/CT fusion imaging with serum and serum CEA and CYFRA21-1(alone or in combination with the χ2 test). Results 68 patients demonstrated bone metastasis with a total of 586 lesions. The incidence of bone metastasis of adenocarcinoma(50/88) was higher than that of squamous cell carcinoma(18/55)(χ2=10.56, P<0.05). The ratio of bone metastatic lesions in adenocarcinoma patients was greater than that in squamous carcinoma(526/586)(χ2=19.23, P<0.05). The serum levels of CEA(Z=4.98, P<0.05) and CYFRA21-1(Z=2.55, P<0.05) in patients with bone metastases were higher than in those without bone metastases. However, no significant correlation was found between serum CEA and bone metastases in non-small cell lung cancer patients with bone metastases(r=0.141, P>0.05), but there was a certain correlation between CYFRA21-1 and the number of bone metastases(r=0.502, P<0.01). Serum CEA and CYFRA21-1 levels were sensitive in the diagnosis of NSCLC bone metastasis(69.1%, 83.8%),but had low specificity(47.6%, 49.3%) and accuracy(57.3%, 65.7%) was low. The SPECT/CT tomographic fusion imaging in the diagnosis of NSCLC bone metastasis had high sensitivity(83.8%), specificity(84.0%), and accuracy(83.9%) were higher than serum CEA(χ2=4.09、23.08、24.33, all P<0.05), specificity and accuracy were higher than CYFRA21-1 (χ2=20.28、12.55, both P<0.05) and whole body bone scan(χ2=21.66、16.05, both P<0.05). The sensitivity(97.0%), specificity(93.3%), and accuracy(95.1%) of SPECT/CT tomographic fusion imaging combined with serum CEA and CYFRA21-1 in the diagnosis of NSCLC bone metastasis were higher than those of whole body bone scan(χ2=12.55、37.17、47.45, all P<0.05), serum CEA(χ2=18.89、38.89、24.33, all P<0.05), CYFRA21-1 (χ2=6.89、35.50、39.17, all P<0.05), sensitivity and accuracy were higher than SPECT/CT tomographic fusion imaging(χ2=6.89、9.53, both P<0.05) applied individually. Conclusions SPECT/CT tomographic fusion imaging combined with serum CEA and CYFRA21-1 diagnosis of NSCLC bone metastases had clinical value because of high sensitivity, specificity, and accuracy.

参考文献/References:

[1] 张一秋, 石洪成, 顾宇参, 等. SPECT/CT骨显像对肺癌骨转移诊断的增益价值[J]. 中华核医学杂志, 2011, 31(4):219-222. DOI:10.3760/cma.j.issn.0253-9780.2011.04.002. Zhang YQ, Shi HC, Gu YS, et al. The added diagnostic value of SPECT/CT imaging for bone metastases from lung cancer[J]. Chin J Nucl Med, 2011, 31(4):219-222.
[2] 王新华, 赵艳萍, 陆海健, 等. SPECT/CT显像诊断转移性骨肿瘤的临床意义[J]. 中华核医学杂志, 2010, 30(2):106-109. DOI:10.3760/cma.j.issn.0253-9780.2010.02.010. Wang XH, Zhao YP, Lu HJ, et al. Clinical value of SPECT/CT imaging in the diagnosis of bone metastasis[J]. Chin J Nucl Med, 2010, 30(2):106-109.
[3] 董科, 石洪成, 刘江, 等. SPECT/CT显像在肿瘤骨转移同一病灶动态随访中的价值[J]. 中华核医学与分子影像杂志, 2013, 33(3):199-202. DOI:10.3760/cma.j.issn.2095-2848.2013.03.011. Dong K, Shi HC, Liu J, et al. Value of SPECT/CT imaging for follow-up of bone metastases[J]. Chin J Nucl Med Mol Imaging,2013, 33(3):199-202.
[4] 赫捷, 赵平, 陈万青. 中国肿瘤登记年报[M]. 北京:军事医学科学出版社, 2012. He J, Zhao P, Chen WQ. China’s annual report on tumor registration[M]. Beijing:Military Medical Science Press, 2012.
[5] 桂文来, 刘增礼, 杨仪, 等. 256例肺癌骨转移核素骨显像的特点分析[J]. 苏州大学学报(医学版), 2005, 25(3):476, 487. DOI:10.3969/j.issn.1673-0399.2005.03.041. Gui WL, Liu ZL, Yang Y, et al. Analysis of characteristics of radionuclide bone imaging in 256 cases of lung cancer with bone metastases[J]. Suzhou Univ J Med Sci, 2005, 25(3):476, 487. DOI:10.3969/j.issn.1673-0399.2005.03.041.
[6] 郭庆志, 吴梅娜, 安彤同, 等. 322例非小细胞肺癌骨转移临床特点及治疗的回顾性分析[J]. 中国肺癌杂志, 2014, 17(9):656-662. DOI:10.3779/j.issn.1009-3419.2014.09.03. Guo QZ, Wu MN, An TT, et al. Characteristics and treatment of bone metastases in 322 cases non-small cell lung cancer:a retrospective study[J]. Chin J Lung Cancer, 2014, 17(9):656-662.
[7] 梁树君, 赵斌, 周绍军, 等. 肺腺癌或鳞状细胞癌患者SPECT/CT全身骨显像诊断骨转移的影像特点及临床价值[J]. 国际肿瘤学杂志, 2015, 42(6):407-409. DOI:10.3760/cma.j.issn.1673-422X.2015.06.002. Liang SJ, Zhao B, Zhou SJ, et al. Characteristics and clinical values of SPECT/CT whole-body bone scanning in detecting bone metastases in patients with lung adenocarcinoma or squamous cell carcinoma[J]. J Int Oncol, 2015, 42(6):407-409.
[8] 宋霞, 陈涛, 王一萍, 等. TSGF、AFP、CEA、CA199、CA50联合检测对消化道恶性肿瘤早期诊断价值[J]. 国际检验医学杂志, 2015, 36(1):118-120. DOI:10.3969/j.issn.16734130.2015.01.053. Song X, Chen T, Wang YP, et al. Combined detection of TSGF, AFP, CEA, CA199 and CA50 for early diagnosis of gastrointestinal cancer[J]. Int J Lab Med, 2015, 36(1):118-120.
[9] Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use[J]. Eur J Cancer, 2007, 43(9):1348-1360. DOI:10.1016/j.ejca.2007.03.021.
[10] 范光磊, 万仁明, 彭鸣亚, 等. 癌胚抗原、糖类抗原15-3及骨转换生化标志物检测对乳腺癌骨转移的诊断意义[J]. 中华核医学与分子影像杂志, 2013, 33(3):203-206. DOI:10.3760/cma.j.issn.2095-2848.2013.03.012. Fan GL, Wan RM, Peng MY, et al. Significance of CEA, CA15-3 and biochemical markers of bone turnover in the diagnosis of bone metastasis from breast cancer[J]. Chin J Nucl Med Mol Imaging, 2013, 33(3):203-206.
[11] 洪军,孙爱军. 血清CEA、CA125、CYFRA21-1、NSE联合检测在肺癌诊断中的应用价值[J]. 河北医药, 2014, 36(5):697-699. DOI:10.3969/j.issn.1002-7386.2014.05.022. Hong J, Sun AJ. Combined detection of serum CEA, CA125, CYFRA21-1 and NSE in the diagnosis of lung cancer[J]. Hebei Med J, 2014, 36(5):697-699.
[12] Szturmowicz M, Rudziński P, Kacprzak A, et al. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer[J]. Pneumonol Alergol Pol, 2014, 82(5):422-429. DOI:10.5603/PiAP.2014.0055.
[13] 赵义刚, 勾正兴. 99Tcm-MDP全身骨显像诊断肺癌骨转移的临床价值[J]. 标记免疫分析与临床, 2016, 23(6):645-647. DOI:10.11748/bjmy.issn.1006-1703.2016.06.014 Zhao YG, Gou ZX. The clinical value of 99Tcm-MDP whole body bone imaging in diagnosing bone metastasis of lung cancer[J]. Labeled Immunoassays &Clin Med, 2016, 23(6):645-647.
[14] 沈维敏, 许佳毅, 唐曦. ECT联合肿瘤标志物检测诊断老年肺癌骨转移的临床观察[J]. 首都医药, 2014, 20:28-29. DOI:10.3969/j.issn.1005-8257.2014.20.016. Shen WM, Xu JY, Tang X. Evaluation of tumor marker and ECT in diagnosis of bone metastasis in elder lung cancers[J]. Capit Med,2014, 20:28-29. DOI:10.3969/j.issn.1005-8257.2014.20.016.
[15] 凌彩霞, 肖国有. SPECT/CT骨断层显像及在恶性肿瘤骨转移诊断中的临床价值[J]. 国际放射医学核医学杂志, 2014, 38(4):275-277. DOI:10.3760/cma.j.issn.1673-4114.2014.04.016. Ling CX, Xiao GY. The clinical value of SPECT/CT bone tomography in the diagnosis of malignant tumor metastasis[J]. Int Radiat Med Nucl Med, 2014, 38(4):275-277.
[16] 张雪辉, 孔飚, 肖国有, 等. SPECT/CT显像对脊柱良恶性病变诊断的增益价值[J]. 中华核医学与分子影像杂志, 2016, 36(2):156-160. DOI:10.3760/cma.j.issn.2095-2848.2016.02.013. Zhang XH, Kong B, Xiao GY, et al. The added value of SPECT/CT imaging for diagnosing benign and malignant lesions of spine[J]. Chin J Nucl Med Mol Imaging, 2016, 36(2):156-160.
[17] 林琳, 刘琳, 贾莹莹, 等. SPECT/CT对骨显像疑难病灶的诊断增益分析[J]. 中国医学影像技术, 2014, 30(4):560-563. DOI:10.13929/j.1003-3289.2014.04.017. Lin L, Liu L, Jia YY, et al. The added diagnostic value of SPECT/CT imaging for difficult lesions[J]. Chin J Med Imaging Technol, 2014, 30(4):560-563.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
　Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[3]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
　Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[4]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[5]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
　LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[6]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
　ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[7]任凌,戴皓洁.125Ⅰ粒子在头颈部腺样囊性癌综合治疗中的作用[J].国际放射医学核医学杂志,2011,35(1):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
　REN Ling,DAI Hao-jie.The effect of 125I seed in comprehensive therapy of the head and neck adenoid cystic carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
[8]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
　LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[9]付晓昉,王秀梅,许建春.放射性榄香烯三羰基铼配合物在荷小细胞肺癌裸鼠体内的分布及其对肿瘤的生长抑制作用[J].国际放射医学核医学杂志,2009,33(6):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
　FU Xiao-fang,WANG Xiu-mei,XU Jian-chun.Anti-tumor effect of elemene tricarbonyl rhenium-188 complex to small cell lung cancer and its biodistribution in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
[10]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
　ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):23.
[11]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[12]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
　Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[13]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[14]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
　YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[15]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
　LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[16]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
　LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[17]吴红宇,贺晓东,刘宇,等.呼吸门控放疗非小细胞肺癌[J].国际放射医学核医学杂志,2011,35(5):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
　WU Hong-yu,HE Xiao-dong,LIU Yu,et al.Respiratory gated radiotherapy for non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
[18]陆光兵,刘丽.125I粒子联合EP方案治疗局部晚期非小细胞肺癌的临床分析[J].国际放射医学核医学杂志,2010,34(2):105.[doi:10.3760/cma.j.issn.1673-4114.2010.02.012]
[19]鲁胜男,冯彦林.18F-FDG PET-CT在评价肺癌化疗疗效中的应用[J].国际放射医学核医学杂志,2010,34(3):164.
　LU Sheng-nan,FENG Yan-lin.The application of 18F-FDG PET-CT in evaluation of the value of lung cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):164.
[20]姚立新,付占昭,顾涛,等.99Tcm-甲氧基异丁基异腈SPECT评价非小细胞肺癌化疗疗效[J].国际放射医学核医学杂志,2009,33(5):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]
　YAO Li-xin,FU Zhan-zhao,GU Tao,et al.99Tcm-methoxyisobutylisonitrile SPECT imaging evaluate chemotherapy of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]

备注/Memo

备注/Memo:
收稿日期:2018-03-27。
通讯作者:刘举珍,Email:liujuzhen2008@qq.com
更新日期/Last Update: 2018-05-25